Fig A1.

Analysis of archival tissue by immunohistochemistry (IHC) failed to demonstrate correlates of treatment benefit. (A) Box plot of median and range of 4E-BP1 IHC scores in patients who experienced disease progression or died within < 6 months of starting the study treatment (failure) versus those alive and free from disease progression at ≥ 6 months (success; median score, 32.5 v 57.5; Wilcoxon rank sum P = .96). (B) Box plot of median and range of ERG-positive cells/mm² in patients who experienced disease progression or died within < 6 months of starting study treatment (failure) versus those alive and free from disease progression (success; median score, 176 v 144; Wilcoxon rank sum P = .38).